0
On Tuesday, D Boral Capital initiated coverage on Tevogen Bio Holdings Inc. (NASDAQ:TVGN), a clinical-stage immunotherapy company.
The company’s lead pipeline product, TVGN-489, is a SARS-CoV-2-specific therapy.
Tevogen’s pipeline includes preclinical programs targeting Epstein-Barr virus-associated lymphomas (TVGN -930), human papillomavirus-related cervical cancer (TVGN -920), multiple sclerosis (TVGN -601), and HPV-related mouth and throat cancer (TVGN-960).
Also Read: Amazon To Launch AI Reasoning Model In June, Reinforcing AWS’s AI Dominance
Analyst Jason Kolbert writes Tevogen stands out by developing off-the-shelf T-cell therapies that address the challenges of traditional treatments.
Its unique technology allows for …
